Skye Bioscience Inc (SKYE): Nemus Bioscience Signs Agreement with Ph...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	118
Boards Moderated	0
Alias Born	02/24/2014

frozenspokes

Re: None

Thursday, 02/14/2019 8:08:03 AM

Thursday, February 14, 2019 8:08:03 AM

Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma

https://finance.yahoo.com/news/nemus-bioscience-signs-agreement-pharmaceuticals-120000003.html

Long Beach, CA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that it has signed an agreement with Pharmaceuticals International Inc. (Pii), a contract development manufacturing organization (CDMO) to develop a sterile eyedrop dosage formulation of NB1111 for human dosing. NB1111 is Nemus’ proprietary prodrug of tetrahydrocannabinol (THC) that is currently undergoing development for the treatment of glaucoma.